Failure of captopril to prevent nitrate tolerance in congestive heart failure secondary to coronary artery disease

The American Journal of Cardiology
N DakakB S Lewis

Abstract

The possible role of angiotensin-converting enzyme inhibition in preventing or minimizing tolerance to intravenous nitroglycerin in severe congestive heart failure (CHF) was studied by quantitating the degree of tolerance in 12 patients receiving nitroglycerin (group 1) and in 9 patients (group 2) receiving nitroglycerin and concurrent treatment with captopril (60 +/- 29 mg/day). At peak effect, nitroglycerin produced almost identical hemodynamic changes in both groups, with significant decreases in right atrial and pulmonary arterial wedge pressure, systolic blood pressure and systemic and pulmonary vascular resistances. Cardiac index increased. The extent of nitrate tolerance was calculated for each hemodynamic parameter as the percentage loss of the peak effect achieved by the drug. At 24 hours, 98 +/- 80% of the benefit achieved with respect to right atrial pressure was lost in group 1 and 61 +/- 74% in group 2 (group 1 vs 2, difference not significant). For pulmonary arterial wedge pressure, 51 +/- 31% (group 1) and 85 +/- 53% (group 2) (difference not significant) of the effect was lost, and for cardiac index, 53 +/- 58% (group 1) and 54 +/- 44% (group 2) (difference not significant). Tolerance was also almost identical r...Continue Reading

References

Jul 1, 1985·Journal of Cardiovascular Pharmacology·J TorresiG J Dusting
Jun 1, 1989·Journal of the American College of Cardiology·S S GottliebM Packer
May 1, 1989·European Heart Journal·H L FungE Kowaluk
Sep 24, 1987·The New England Journal of Medicine·M PackerM Yushak
Jan 1, 1987·British Heart Journal·J BaylissP Poole-Wilson
Jul 1, 1981·The American Journal of Medicine·W S ColucciE Braunwald

❮ Previous
Next ❯

Citations

Aug 1, 1994·Cardiovascular Drugs and Therapy·U Thadani, R J Lipicky
Jun 1, 1994·Cardiovascular Drugs and Therapy·H L Fung, J A Bauer
Jun 1, 1994·Cardiovascular Drugs and Therapy·J Dupuis
Aug 1, 1993·Journal of the American College of Cardiology·I T MeredithR W Harper
May 30, 1996·The American Journal of Cardiology·R A Kelly, T W Smith
May 30, 1996·The American Journal of Cardiology·U Elkayam
Sep 6, 2003·International Journal of Cardiology·Teruo InoueShigenori Morooka
Dec 29, 2000·Journal of the American College of Cardiology·D Hébert, J Y Lam
Aug 1, 1992·British Journal of Clinical Pharmacology·J C Cowan
Jul 26, 2008·The Journal of Pharmacology and Experimental Therapeutics·Pei-Suen TsouHo-Leung Fung
Sep 14, 2014·Heart Failure Clinics·Robert T ColeJaved Butler
Mar 26, 2014·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Udho Thadani
Sep 24, 1992·The American Journal of Cardiology·U ElkayamE Ostrzega
Jun 15, 1994·International Journal of Cardiology·M Ferratini
Jul 1, 1994·American Heart Journal·N J Mangione, S P Glasser
Nov 18, 2003·British Journal of Clinical Pharmacology·Katherine E FayersDavid W Laight
Mar 14, 2014·JACC. Heart Failure·Divya GuptaJaved Butler
Jan 29, 2005·Journal of Cardiovascular Pharmacology and Therapeutics·Uri ElkayamMahyar Derakhshani
Feb 25, 2018·Current Heart Failure Reports·Prabhjot SinghJaved Butler
Oct 8, 1999·Journal of Cardiovascular Pharmacology·G BerkenboomJ Fontaine

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.